Discover published sets by community

Serotonin-Norepinephrine Reuptake Inhibitors elevate serotonin and norepinephrine levels, treating major depressive disorder, anxiety, and sometimes chronic pain.

They inhibit the reuptake of norepinephrine and serotonin, treating depression, chronic pain, and sometimes insomnia.

They enhance the effect of the neurotransmitter GABA and are used for anxiety disorders, insomnia, seizures, and alcohol withdrawal.

They block the effects of adrenaline on beta receptors, thus reducing physical symptoms of anxiety such as tachycardia and tremors.

Lithium modulates neurotransmitter release and supports neuroplasticity, used primarily in the management of bipolar disorder.

They have various mechanisms including SSRI, SNRI, and others, and they treat depression, with generally fewer side effects compared to older antidepressants.

Monoamine Oxidase Inhibitors prevent the breakdown of monoamine neurotransmitters, treating depression and anxiety, but have dietary restrictions due to potential hypertensive crisis.

They increase dopamine and norepinephrine activity, used mainly to treat Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy.

Selective Serotonin Reuptake Inhibitors increase serotonin levels in the brain and are used to treat depression and anxiety.

They block NMDA glutamate receptors and are used in the management of Alzheimer's disease to slow down progression.

They inhibit the enzyme acetylcholinesterase, which leads to increased acetylcholine in the brain, and are used to treat Alzheimer's disease.

They primarily block D2 dopamine receptors and are used to treat schizophrenia but can cause extrapyramidal symptoms.

They block dopamine D2 receptors and serotonin receptors, treating schizophrenia, bipolar disorder, and depression augmentation.

They decrease neuronal excitability and are used for bipolar disorder, seizure disorders, and sometimes neuropathic pain.